February 2015 | OncologyLive

SABCS Studies Highlight Promise and Complexity in Targeting PI3K in Breast Cancer

February 09, 2015

Although there is a significant scientific rationale for targeting the PI3K pathway in breast cancer, research findings presented recently at the 2014 San Antonio Breast Cancer Symposium (SABCS) highlight the inherent complexities in using agents directed at this cell-signaling network.

PD-1 Researchers Excited About Prospects for Checkpoint Strategy in Hodgkin Lymphoma

February 08, 2015

Amid continuing excitement over the potential for PD-1 pathway immune checkpoint blockade strategies in anticancer therapies, research presented at the 2014 American Society of Hematology (ASH) Annual Meeting helped established a foundation for the use of anti- PD-1/PD-L1 agents in hematologic malignancies.

Molecular Diagnostics in CML Illustrate Ways to Enhance Well-Established Strategies

January 30, 2015

Although there clearly are a number of worthy candidates for the single most influential event that unequivocally proclaimed the beginning of the modern era of precision cancer medicine, there would surely be many votes for the impact of imatinib on the course of the natural history of chronic myeloid leukemia.